Last reviewed · How we verify
Psoriatic Immune Response to Tildrakizumab
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Details
| Lead sponsor | University of California, San Francisco |
|---|---|
| Phase | PHASE4 |
| Status | UNKNOWN |
| Enrolment | 10 |
| Start date | Thu Sep 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Sep 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Psoriasis Vulgaris
Interventions
- Tildrakizumab Prefilled Syringe
Countries
United States